Medical Predictive Science Corporation

Medical Predictive Science Corporation (MPSC) develops the HeRO (Heart Rate Characteristics) System, an FDA-cleared predictive monitoring platform for neonatal intensive care. HeRO uses proprietary algorithms to detect subtle irregularities in heart rate variability that precede patient deterioration by hours to days, providing early warning for sepsis, necrotizing enterocolitis (NEC), urinary tract infections, meningitis, respiratory decompensation, brain pathology, and mortality risk. The technology analyzes cytokine-driven changes in autonomic nervous system response during early infection and inflammatory events, generating hourly risk scores for infection in the subsequent 24 hours. Clinical evidence from the largest randomized controlled trial in neonatology (3,003 very low birthweight infants) demonstrated a 22% reduction in overall mortality and 40% reduction in mortality among infected patients, with average diagnostic timing improvement of 18+ hours—enabling earlier antibiotic intervention before systemic progression. HeRO operates as a standalone bedside monitor or embedded module within compatible central monitoring systems.